How do I transition a patient who is stable on oral Invega (paliperidone) 12 mg daily to the long‑acting injectable formulation?

Transitioning from Oral Invega 12mg to Invega LAI

Start Invega Sustenna (paliperidone palmitate once-monthly) at 234 mg (150 mg eq.) on Day 1 in the deltoid muscle, followed by 156 mg (100 mg eq.) on Day 8 in the deltoid, then continue with monthly maintenance doses of 117 mg (75 mg eq.) starting on Day 36—no oral supplementation is needed, and you can discontinue the oral Invega the day before starting the LAI. 1, 2

Initiation Protocol

The FDA-approved loading regimen is designed to achieve therapeutic plasma levels rapidly without oral overlap:

• Day 1: 234 mg (150 mg eq.) deltoid injection
• Day 8 (±2 days): 156 mg (100 mg eq.) deltoid injection
• Day 36 and monthly thereafter: 117 mg (75 mg eq.) maintenance dose (deltoid or gluteal)

Needle Selection for Deltoid Injections

• <90 kg body weight: Use 1-inch, 23-gauge needle
• ≥90 kg body weight: Use 1.5-inch, 22-gauge needle
• Gluteal injections (maintenance only): Always use 1.5-inch, 22-gauge needle 1, 2

Timing of Oral Discontinuation

Stop oral Invega 12 mg the day before initiating the LAI. The loading dose regimen is specifically designed to eliminate the need for oral supplementation during the transition period. 1, 2, 3 Research using quantitative systems pharmacology modeling confirms that starting PP1M one day after the last oral dose provides optimal benefit-risk compared to delayed starts or overlapping strategies. 3

Dose Equivalency Rationale

Your patient on oral Invega 12 mg daily falls within the therapeutic range studied in clinical trials (3-15 mg daily). 4 The standard initiation protocol (234 mg → 156 mg) is appropriate regardless of the specific oral dose, as it rapidly achieves therapeutic plasma concentrations across the dosing spectrum. The recommended maintenance dose of 117 mg (75 mg eq.) monthly corresponds roughly to mid-range oral dosing. 1, 2

If you need to adjust maintenance dosing, the range is 39-234 mg (25-150 mg eq.) monthly, with flexibility of ±7 days for monthly injections. 1, 2

Critical Pitfalls to Avoid

• Do not continue oral paliperidone after starting the LAI—the loading regimen eliminates this need and continuing oral medication risks excessive dopamine D2 receptor blockade and increased side effects
• Do not skip the Day 8 dose—this second loading dose is essential for maintaining therapeutic levels before the first monthly maintenance dose
• Do not use gluteal site for loading doses—deltoid administration is required for Days 1 and 8 to ensure proper absorption kinetics 1, 2
• Do not delay the first LAI dose by a week—modeling studies show this creates a transient undertreatment window 3

Special Considerations

If your patient has mild renal impairment (CrCl 50-80 mL/min), adjust the initiation regimen to 156 mg on Day 1,117 mg on Day 8, and 78 mg monthly maintenance. 1, 2 No adjustment is needed for hepatic impairment unless severe (no data available for severe hepatic impairment).

The transition strategy is supported by both FDA labeling 4 and population pharmacokinetic modeling that simulated 5000 patient profiles to ensure therapeutic coverage during the switch. 1, 2